Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A Pharmacological Perspective on the Study of Taste.

Palmer RK.

Pharmacol Rev. 2019 Jan;71(1):20-48. doi: 10.1124/pr.118.015974. Review.

PMID:
30559245
2.

A high throughput in vivo assay for taste quality and palatability.

Palmer RK, Long D, Brennan F, Buber T, Bryant R, Salemme FR.

PLoS One. 2013 Aug 12;8(8):e72391. doi: 10.1371/journal.pone.0072391. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/6a76b80f-015c-4749-9b11-e3db355726e3.

3.

TRP channels as targets for therapeutic intervention in obesity: focus on TRPV1 and TRPM5.

Palmer RK, Lunn CA.

Curr Top Med Chem. 2013;13(3):247-57. Review.

PMID:
23432058
4.

Immunotoxicology: fifty years of global scientific progress.

McKarns SC, Kerkvliet NI, Dean JH, Bonn MB, Cohen MD, Franko J, Laiosa MD, Lawrence BP, Luebke RW, Luster MI, Miller PG, Palmer RK, Pfau JC, Raman P, Regal JF, Rodgers KE, Schondelmeyer RS, Zhang X, Burns-Naas LA.

J Immunotoxicol. 2012 Oct-Dec;9(4):339-40. doi: 10.3109/1547691X.2012.658530. Epub 2012 Oct 19.

PMID:
23078377
5.

A generalized model and high throughput data analysis system for functional modulation of receptor-agonist systems suitable for use in drug discovery.

Pawlyk AC, Palmer RK, Sprous D, Allee C.

Comb Chem High Throughput Screen. 2013 Mar;16(3):199-209.

PMID:
22934943
6.

Antibacterial agent triclosan suppresses RBL-2H3 mast cell function.

Palmer RK, Hutchinson LM, Burpee BT, Tupper EJ, Pelletier JH, Kormendy Z, Hopke AR, Malay ET, Evans BL, Velez A, Gosse JA.

Toxicol Appl Pharmacol. 2012 Jan 1;258(1):99-108. doi: 10.1016/j.taap.2011.10.012. Epub 2011 Oct 20.

PMID:
22036726
7.

Triphenylphosphine oxide is a potent and selective inhibitor of the transient receptor potential melastatin-5 ion channel.

Palmer RK, Atwal K, Bakaj I, Carlucci-Derbyshire S, Buber MT, Cerne R, Cortés RY, Devantier HR, Jorgensen V, Pawlyk A, Lee SP, Sprous DG, Zhang Z, Bryant R.

Assay Drug Dev Technol. 2010 Dec;8(6):703-13. doi: 10.1089/adt.2010.0334.

PMID:
21158685
8.

Inorganic arsenite inhibits IgE receptor-mediated degranulation of mast cells.

Hutchinson LM, Trinh BM, Palmer RK, Preziosi CA, Pelletier JH, Nelson HM, Gosse JA.

J Appl Toxicol. 2011 Apr;31(3):231-41. doi: 10.1002/jat.1585. Epub 2010 Sep 14.

PMID:
20842677
9.

QSAR in the pharmaceutical research setting: QSAR models for broad, large problems.

Sprous DG, Palmer RK, Swanson JT, Lawless M.

Curr Top Med Chem. 2010;10(6):619-37. Review.

PMID:
20337590
10.

Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay.

Long DJ, Devantier HR, Brennan FX, Bryant RW, Salemme FR, Palmer RK.

J Pharmacol Exp Ther. 2010 Feb;332(2):525-30. doi: 10.1124/jpet.109.155416. Epub 2009 Nov 10.

11.

Quantitative assessment of TRPM5-dependent oral aversiveness of pharmaceuticals using a mouse brief-access taste aversion assay.

Devantier HR, Long DJ, Brennan FX, Carlucci SA, Hendrix C, Bryant RW, Salemme FR, Palmer RK.

Behav Pharmacol. 2008 Oct;19(7):673-82. doi: 10.1097/FBP.0b013e3283123cd6.

PMID:
18797244
12.

The pharmacology and signaling of bitter, sweet, and umami taste sensing.

Palmer RK.

Mol Interv. 2007 Apr;7(2):87-98. Review.

PMID:
17468389
13.

Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells.

Fossetta J, Jackson J, Deno G, Fan X, Du XK, Bober L, Soudé-Bermejo A, de Bouteiller O, Caux C, Lunn C, Lundell D, Palmer RK.

Mol Pharmacol. 2003 Feb;63(2):342-50.

14.

Agonist action of adenosine triphosphates at the human P2Y1 receptor.

Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK.

Mol Pharmacol. 1998 Dec;54(6):1118-23.

15.

Evidence that the p2y3 receptor is the avian homologue of the mammalian P2Y6 receptor.

Li Q, Olesky M, Palmer RK, Harden TK, Nicholas RA.

Mol Pharmacol. 1998 Sep;54(3):541-6.

16.

Intra- and intercellular calcium signaling in human neuroepithelioma cells.

Palmer RK, Yule DI, McEwen EL, Williams JA, Fisher SK.

J Lipid Mediat Cell Signal. 1996 Sep;14(1-3):169-74. Review.

PMID:
8906559
17.

Paracrine mediation of calcium signaling in human SK-N-MCIXC neuroepithelioma cells.

Palmer RK, Yule DI, Shewach DS, Williams JA, Fisher SK.

Am J Physiol. 1996 Jul;271(1 Pt 1):C43-53.

PMID:
8760029
18.

Agonist-specific calcium signaling and phosphoinositide hydrolysis in human SK-N-MCIXC neuroepithelioma cells.

Palmer RK, Yule DI, McEwen EL, Williams JA, Fisher SK.

J Neurochem. 1994 Dec;63(6):2099-107.

19.

Disparity between blood pressure and PRA inhibition after administration of a renin inhibitor to anesthetized dogs: methodological considerations.

Palmer RK, Rapundalo ST, Batley BL, Barnes AE, Singh S, Ryan MJ, Taylor DG Jr.

Clin Exp Hypertens. 1993 Jul;15(4):663-81.

PMID:
8374609
20.

Drug-reinforced responding: rapid determination of dose-response functions.

Winger G, Palmer RK, Woods JH.

Drug Alcohol Depend. 1989 Oct;24(2):135-42.

21.

Committee report on economic, administrative and legal factors influencing the insurability and employability of patients with ischemic heart disease.

Guillette W, Judge RD, Koehn E, Miller JE, Palmer RK, Tremblay JL.

J Am Coll Cardiol. 1989 Oct;14(4):1010-5. No abstract available.

22.

Insurance company experience with coronary bypass surgery.

Mast J, Palmer RK.

Med Sect Proc. 1986:107-17. No abstract available.

PMID:
3496593

Supplemental Content

Loading ...
Support Center